Abstract
High dose cytarabine (HiDAC) is the most effective single agent studied to date for the treatment of acute myeloid leukemia (AML); clofarabine (CLOF) is also an active single agent in AML. Preclinical data suggest synergy between cytarabine and clofarabine. Based on the results of a limited phase 1 trial (
Blood
2006
; 108
: 221b
Disclosures: Powell:Genzyme Oncology: Research Funding. Off Label Use: Clofarabine is not approved for treatment of AML.
Author notes
Corresponding author
2008, The American Society of Hematology
2008
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal